Industry Information

Update September 17, 2021

"Unable to make drugs" targets finally become history, KRAS inhibitor breakout contest kicks off

Recently, Cinda Biotech and Jinfang Pharmaceutical reached a licensing agreement to obtain the latter's exclusive global development and commercialization rights for the KRAS G12C inhibitor GFH925 in...

Update September 16, 2021

Hengrui Medicine's application for the treatment of HER2-positive breast cancer with pyrrotinib has been accepted

According to the data of Yaozhi, Hengrui Medicine's application for the new indications of pyrrotinib maleate tablets was accepted by CDE. According to a press release issued by Hengrui Medicine, the...

Update September 15, 2021

Corning Jerry/ Simcere's PD-L1 combined with lenvatinib was approved for the treatment of endometrial cancer

On September 15, 2021, Corning Jereh and Simcere announced that the clinical trial application of Envolimab Injection (R&D code: KN035) combined with Lenvatinib mesylate was approved by the...

Update September 13, 2021

Heavy! The special procurement of insulin national procurement officially started, involving 81 products from 10 companies

Just now, Shanghai Sunshine Pharmaceutical Purchasing Network issued the notice of "The sixth batch of nationally organized drug centralized procurement (insulin special) related companies and...

Update September 10, 2021

HER2 ADC innovation wave! Kelun, Rongchang, Fosun...what are their competitive strengths?

It is reported that at the upcoming ESMO this year, the head-to-head DESTINY-Breast03 research results of DS-8201 and T-DM1 will be unveiled in the form of "Latest Breaking Abstract" (LBA,...

Update September 09, 2021

To challenge the target of "unable to make a drug", Huadong Medicine and British Silicon Intelligence cooperate to develop innovative anti-tumor drugs

On September 8, 2021, Huadong Medicine (SZ.000963) and Insilico Medicine announced today that they have established a partnership to jointly accelerate the research and development of innovative...

Update September 08, 2021

These pharmaceutical companies will be intensively monitored! A new round of major adjustments is coming

Recently, the General Office of the National Health Commission issued a notice on the "Regulations for the National Key Monitoring and Reasonable Use of Drugs Catalogue Adjustment" (Guoweiban Medical...

Update September 07, 2021

Hengrui Medicine's SHR-1701 injection and bevacizumab injection were approved for clinical trials

On September 6, Hengrui Medicine issued an announcement stating that its subsidiary Shengdia Biomedicine had recently received NMPA’s approval and issuance of the "Drug Clinical Trial Approval...

Update September 06, 2021

3 new drugs are planned to be included in breakthrough therapy! From Hutchison Medicine, Haihe Medicine, Amgen

According to the latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, Haihe Pharmaceuticals/Shanghai Institute of Materia Medica, Chinese...

Update September 04, 2021

The first company to pass the evaluation, Hengrui Medicine's contrast agent ioverol injection passed the consistency evaluation of generic drugs

On September 2, Hengrui Medicine announced that it had received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, approving the...